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High-Risk Cardiovascular Patients: 
Clinical Features, Comorbidities, and 
interconnecting Mechanisms
Katharina Andrea Schuett† , Michael Lehrke† , Nikolaus Marx and Mathias Burgmaier*
Department of Internal Medicine I, University Hospital RWTH Aachen, Aachen, Germany
Cardiovascular disease is the leading cause of death in the Western world with an 
increase over the last few decades. Atherosclerosis with its different manifestations in 
the coronary artery tree, the cerebral, as well as peripheral arteries is the basis for car-
diovascular events, such as myocardial infarction, stroke, and cardiovascular death. The 
pathophysiological understanding of the mechanisms that promote the development 
of vascular disease has changed over the last few decades, leading to the recognition 
that inflammation and inflammatory processes in the vessel wall are major contributors 
in atherogenesis. In addition, a subclinical inflammatory status, e.g., in patients with 
diabetes or the presence of a chronic inflammatory disease, such as rheumatoid arthritis, 
have been recognized as strong risk factors for cardiovascular disease. The present 
review will summarize the different inflammatory processes in the vessel wall leading to 
atherosclerosis and highlight the role of inflammation in diabetes and chronic inflamma-
tory diseases for cardiovascular morbidity and mortality.
Keywords: atherosclerosis, type 2 diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, 
coagulation, inflammation, cardiovascular disease
iNTRODUCTiON
Cardiovascular disease is the leading cause of death in the western world with an increase over the 
last few decades (1–4).
Atherosclerosis may result in myocardial infarction (MI), stroke, or peripheral artery disease 
according to its manifestations in the coronary artery tree, in cerebral arteries as well as peripheral 
arteries. The pathophysiological understanding of the mechanisms that promote the development of 
vascular disease has changed over the last few decades, leading to the recognition that inflammation 
and inflammatory processes in the vessel wall are major contributors in atherogenesis (5).
ATHeROGeNeSiS
For decades, atherogenesis has been seen as a degenerative process in the vessel wall leading to the 
progressive occlusion of the artery up to a certain point where a few activated platelets are sufficient 
to occlude the vessel and cause cardiac events, such as acute MI. In the 1990s, we learned from 
our pathology colleagues that a majority of lesions causing an acute coronary syndrome show a 
stenosis <50%, and further pathological analysis revealed that most of these lesions are the so-
called unstable lesions (6). These lesions are characterized by a high inflammatory burden of cells, 
such as monocytes and T cells, and a large necrotic lipid core as well as a very thin fibrous cap 
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making the atherosclerotic lesion prone to rupture. At the same 
time, experimental data have shown that atherogenesis is an 
inflammatory process in the vessel wall in different phases and 
stages (7). Also not strictly defined endothelial dysfunction, fatty 
streak formation and the formation of advanced and potentially 
complicated lesions have been described as the main phases in 
lesion development (8). Over the last decade, our understanding 
of the inflammatory cells involved in these processes has grown. 
The characteristic cell type of an atherosclerotic lesion is the lipid-
loaden macrophage which is attracted by certain chemokines to 
the vessel wall and then can contribute to the local inflammatory 
response by the expression and release of inflammatory media-
tors. The uptake of LDL in these mononuclear cells by scavenger 
receptors results in the characteristic foam cell. In addition, the 
accumulation of cholesterol within macrophages leads to crystal 
formation, and these intracellular microcrystals can activate the 
inflammasome of the cells subsequently resulting in the release 
of cytokines (9). Interestingly, experimental work from various 
groups around the world has shown that different subtypes of 
macrophages can be found in atherosclerotic lesions with the 
predominance of the M1-subpopulation which release proin-
flammatory cytokines (10). Additional cellular components of 
the innate immune response in the vessel wall are mast cells and 
to a certain extent polymorphonuclear leukocytes, but the latter 
have mainly been found in murine models, and the relevance 
for human atherosclerosis remains unclear (11). In addition to 
the innate immune response, clinical and experimental data 
support the recognition that the adaptive immune system is of 
critical importance in atherogenesis. As such, dendritic cells 
have been identified as a critical “link” between the innate and 
adaptive immune responses by initiating T-cell response. T cells 
in the atherosclerotic lesion are mainly CD4 cells which to a large 
extent release proinflammatory Th1 cytokines. These cytokines, 
such as interferon (IFN)-γ and tumor necrosis factor (TNF)-α, 
do not only induce the expression of certain chemokines thus 
favoring the recruitment of additional leukocytes but also lead 
to the activation of other vascular cells [reviewed in Ref. (12)].
In addition, recent work has shown that so-called regula-
tory T cells are an important atheroprotective cell population 
in the vascular wall through their capacity to control effector 
T cells (13).
The recognition that inflammation plays an important role in 
atherogenesis has been paralleled by the clinical observation that 
elevated levels of high-sensitive C-reactive protein (hsCRP) is a 
useful biomarker to predict cardiovascular events in patients (14). 
Elevated levels of hsCRP are associated with an increased risk for 
MI and major cardiovascular events in a primary prevention pop-
ulation. In addition, a clinical trial with stratification of patients 
according to their CRP levels has shown that the implementation 
of a lipid lowering therapy by statins is of greatest benefit in those 
subjects that exhibited elevated levels of the inflammatory marker 
hsCRP (15).
COAGULATiON AND iNFLAMMATiON
Over the last two decades, experimental data have shown an 
interaction of inflammation with procoagulatory mechanisms 
in the vessel wall: inflammatory cells, such as macrophages and 
T lymphocytes, produce cytokines leading to the expression of 
tissue factor (TF) by endothelial cells, macrophages, and smooth 
muscle cells (SMCs), thus enhancing prothrombotic properties 
of the plaque (16). However, the interaction of inflammation and 
coagulation is not limited to the vessel wall. In obesity, which 
is frequently associated with cardiovascular disease and diabe-
tes, adipose tissue is a major source for elevated inflammatory 
cytokines (17, 18). Macrophages and T lymphocytes produce 
IFN-γ, interleukin (IL)-6, monocyte chemotactic protein (MCP)-
1, TNF-α, and PAI-1 (19), which are all able to impact on the 
coagulation system (Figure 1). Not only inflammatory cytokines 
but also the complement system interacts with coagulation. The 
complement system is an important immune surveillance system 
with over 30 components involved. It can be activated by three 
different pathways, the classical, the lectin, and the alternative 
pathway (20). Activation of any of these consequently results 
in activation of complement C3, the central component of the 
complement system. Subsequently, complement C5 is activated 
leading to the formation of the terminal complement complex 
(C5b, C6, C7, C8, and C9). The biological functions of the comple-
ment system are broad including, among others, innate immune 
responses and coagulation (21). In coagulation, complement 
affects both platelet function and fibrin clot structure and lysis.
Primary Hemostasis
Following plaque rupture, thrombosis is initiated when throm-
botic components of the plaque are exposed to circulating blood. 
Platelets are the first to respond and following their adhesion, 
platelets are activated leading to additional recruitment and 
aggregation with stabilization of the clot (22). In addition, 
inflammation can alter platelet function (Figure 1). Early changes 
include endothelial dysfunction with decreased nitric oxide (NO) 
production. NO is a key player in negative regulation of platelet 
activity, and decreased levels result in hyper-reactivity of platelets 
(23).
In addition to their primary role in hemostasis, platelets actively 
participate in inflammatory and immune processes. They carry 
a multiplicity of chemokines and cytokines, which are mostly 
found within the various platelet granules. Platelet activation and 
consequent degranulation result in the release of chemokines, 
including CXC-chemokine ligand 1 (CXCL1), platelet factor 4 
(also known as CXCL4), CXCL5 and CXCL7, CC-chemokine 
ligand 3 [CCL3; also known as macrophage inflammatory protein 
1 alpha (MIP-1α)], CCL5 [also known as regulated on activation, 
normal T Cell expressed and secreted (RANTES)], and CCL7, ILs 
(IL-1β, IL-7, and IL-8), prostaglandins, and the transmembrane 
protein CD154 (24, 25). CD154 interacts with CD40 on endothe-
lial cells leading to an upregulation of cell adhesion molecules 
on endothelial cells, including intercellular adhesion molecule 1 
(ICAM1) and vascular cell adhesion molecule 1 (VCAM1), and 
the release of CC-chemokine ligand-2 (CCL2), thereby facilitating 
leukocyte recruitment to the inflammatory site (26). In addition, 
activated platelets also release soluble CD154 likewise leading 
to an upregulation of vascular cell adhesion molecules and the 
release of IL-6. Through the expression of these chemokines, 
cytokines, CD154, and cell adhesion molecules, activated platelets 
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promote neutrophil tethering and activation. Furthermore, they 
also activate monocytes and dendritic cells, particularly through 
the CD154–CD40 interaction (24). For an extended overview 
about this topic, see the review article of Semple et al. (24).
Complement and platelets interact on different levels. Platelets 
contain several complement receptors as well as complement 
regulatory molecules, and several components of the comple-
ment cascade have been recognized on the platelet surface. 
Complement activation can be initiated by several platelet ago-
nists, such as adenosindiphosphate (ADP), epinephrine, arachi-
donic acid, thrombin, and exposure to shear stress (27). However, 
a study using complement C3 knock-out mice revealed C5 con-
vertase activity of thrombin suggesting a platelet-independent 
mechanism of complement activation (28). The other way round, 
several complement components are known to activate platelets 
including the mannose-binding lectin (MBL)/MBL-associated 
serine protease (MASP) complex, binding of C1q to its recep-
tor as well as the complement C3 cleavage products (iC3b, C3d, 
and C3dg) to their receptors CR2 and CR3 (only for iC3b) (27, 
29–31). In  vitro studies further suggest that activated platelets 
bind the anaphylatoxins C3a and C5a resulting in platelet aggre-
gation (32, 33). In addition to classical complement receptors, 
P-selectin binds C3b resulting in the generation of C3a and the 
terminal complement complex C5b–9, thereby enhancing platelet 
response (34, 35). Furthermore, the anaphylatoxins C3a and C5a 
are generated which are known to have cytokine-like properties 
with enhanced leukocyte recruitment and support of the general 
inflammatory response (27). Under normal circumstances, 
complement activation is tightly regulated due to expression of 
complement regulatory molecules. On the platelet surface, fac-
tor H inactivates C3b and destabilizes the C3 convertase (36). 
Similarly, membrane cofactor (MCP or CD46) inactivates C3b, 
and decay-accelerating factor (DAF or CD55) interferes with 
C3 convertase. Furthermore, CD59 is known to destabilize the 
terminal complement complex (35).
Secondary Hemostasis
Fibrin clot structure plays a crucial role in determining predispo-
sition to atherothrombotic events. Clots with compact structure 
and impaired fibrinolysis are associated with premature and more 
severe cardiovascular disease.
Inflammatory cytokines produced by macrophages and T 
lymphocytes, including IFN-γ, IL-6, MCP-1, and TNF-α, are able 
to influence both clot structure and lysis (Figure 1). By leading to 
increased production of acute phase products, such as fibrinogen 
and PAI-1, they alter clot structure and prolong fibrinolysis, 
thereby enhancing the prothrombotic milieu (19, 37). TF, the key 
initiator of the coagulation cascade, is produced by various cell 
types with monocytes being a major source. TF expression is very 
low under basal conditions (38) but increases upon stimulation 
with cytokines (i.e., TNF-α and IL-1β) resulting in activation of 
the coagulation system (39–41).
Complement interacts with the fluid phase of coagulation at 
different levels. Mannose-associated serine protease 1 (MASP-1) 
exhibits a thrombin-like profile by activating fibrinogen and 
FXIII. It thereby leads to the formation of a crosslinked fibrin 
clot although the catalytic efficiency compared with thrombin 
is greatly reduced (42). Furthermore, MASP-1 is able to induce 
FiGURe 1 | Low-grade inflammation and coagulation. Low-grade inflammation results in platelet dysfunction and the formation of a denser clot structure and 
hypofibrinolysis. Following activation or apoptosis various cell types release microparticles which contain procoagulants. Activation of neutrophils causes the release 
of neutrophil extracellular traps (NETs), which display procoagulant properties including platelet activation.
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prothrombin and thrombin activatable fibrinolysis inhibitor 
(TAFI), altogether leading to the formation of thinner fibrin 
fibers and longer lysis time (43). Similarly, MASP-2 cleaves 
prothrombin to thrombin (42, 44). The C1 inhibitor not only 
inhibits C1r/s, MASP-1, and MASP-2 but also inhibits FXIIa and 
FXIa (45). Shats-Tseytlina demonstrated already in 1994 that the 
activation of the complement cascade leads to the formation 
of a prothrombotic clot with thinner fibers. Using proteom-
ics analysis, complements C1, C3, C4, C5a, and factor B were 
demonstrated in plasma clots (46). Of these, C3 binds with high 
affinity to fibrinogen leading to a prothrombotic clot structure 
and prolongation of clot lysis in vitro (47, 48). In addition to com-
plement C3, C5a is known to induce TF and PAI-1 expressions 
(49, 50). Activation of the complement system and generation 
of the terminal C5b–9 complex further induce endothelial cells 
to produce TF and vWF thereby generating a prothrombotic 
phenotype (51).
Microparticles
Microparticles (MPs) are cell membrane-derived particles that 
can promote both coagulation and inflammation (Figure  1). 
Following activation or apoptosis, they are released from various 
cell types, including platelets, endothelial cells, red blood cells, 
and leukocytes. Depending on their origin they vary in size 
(0.2–1 μm) and their membrane composition of phospholipids 
and proteins. MPs can be detected in the circulation of healthy 
control individuals and are elevated in inflammatory situations, 
such as sepsis (52) and diabetes mellitus (53). MPs are directly 
able to modulate nitric oxide production from endothelial cells, 
induce cytokine release and prostacycline production as well as 
adherence of monocytes to the endothelium (54). The two major 
procoagulants found on the surface of MPs are phosphatidylser-
ine and TF (55) thereby contributing to a prothrombotic state 
in various diseases. Furthermore, MPs can harbor and transport 
microRNA thereby impacting protein expression of target cells 
(56, 57).
Neutrophil extracellular Traps
Activation of neutrophils causes the release of web-like structures 
of DNA, so-called neutrophil extracellular traps (NETs). Studies 
demonstrated NETs to display procoagulatory properties, includ-
ing the induction of platelet adhesion, aggregation, and fibrin 
deposition on their surface. Histones, cationic proteins that are 
associated with DNA, can be actively secreted by activated inflam-
matory cells, such as neutrophils, contributing to the formation of 
NETs. In this context, they have been shown to promote platelet 
aggregation and thrombin formation through platelet-dependent 
mechanisms, including platelet toll-like receptor (TLR) 2 and 
TLR4 (58). Bosmann and colleagues demonstrated complement 
C5a to be able to trigger the appearance of histones by binding 
to its receptors C5aR and C5L2 (59), thereby contributing to 
an increased inflammatory and prothrombotic milieu. A more 
recent study in acute STEMI demonstrated that the interaction 
of thrombin-activated platelets with polymorphonuclear neutro-
phils at the site of plaque rupture results in local NET formation 
and delivery of active TF (60).
ATHeROSCLeROSiS iN PATieNTS wiTH 
CHRONiC iNFLAMMATORY DiSeASeS
As highlighted above, atherosclerosis is characterized by an 
inflammatory process in the vessel wall (61). Thus, inflammatory 
biomarkers and cytokines, such as hsCRP, have been related with 
progressive cardiovascular disease as well as an increased risk for 
cardiovascular events (14, 62–65). On the other hand, patients 
with a chronic high state of inflammation, such as autoimmune 
diseases, including rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE), are at a high risk for cardiovascular morbid-
ity and mortality, and the increased cardiovascular risk of these 
patients is related to the extent of inflammation (66) (Figure 2). 
However, the underlying pattern, pathophysiology, and pheno-
type of this increased cardiovascular risk in patients with chronic 
inflammation vary between diseases and are discussed below for 
RA and SLE.
Rheumatoid Arthritis
Patients with RA exhibit an increased cardiovascular risk with 
higher rates of sudden cardiac death and unrecognized MI 
compared with age- and sex-matched patients without RA (67). 
Furthermore, atherosclerosis starts early and is more diffuse over 
multiple vascular beds in this high-risk group (68). It could be 
demonstrated that patients with RA and diabetes share similar 
frequency and severity regarding preclinical atherosclerosis 
(69). An autopsy study of 41 patients with RA and 82 age- and 
sex-matched controls revealed a higher incidence of vulnerable 
plaques in the left anterior descending coronary artery and 
more plaque inflammation in patients with RA (70). Recently, 
a study by Karpouzas et al. analyzed plaque morphology using 
CT angiography and found a higher atherosclerotic burden in 
patients with RA. Interestingly, disease activity was associated 
with the presence of non-calcified and mixed, but not calcified 
plaques in this study, suggesting that disease activity is associ-
ated with plaque vulnerability (71). In light of these data, it is 
tempting to speculate that a more vulnerable plaque phenotype 
is responsible for the increased cardiovascular risk in patients 
with RA. Furthermore, these findings are in line with an 
increased prevalence of traditional cardiovascular risk factors, 
such as diabetes mellitus, hypertension, smoking, and obesity, 
in patients with RA [for review, see Ref. (72)]. However, several 
studies demonstrated that the cardiovascular risk in patients 
with RA following adjustment for classical cardiovascular risk 
factors remained high, suggesting that the increased risk in these 
patients cannot be fully explained by classical cardiovascular 
risk factors (67, 73). Vice versa, traditional cardiovascular risk 
assessment models are of limited value in patients with RA and 
should thus be used with caution in this high-risk group (74). 
Taken together, these data emphasize the link between systemic 
inflammation on the one hand and atherothrombosis on the 
other hand. However, patients with RA are not solely character-
ized by increased atherothrombosis but also by high rates of 
valvular heart disease, myocarditis, and non-ischemic cardiac 
failure, which all contribute to the increased cardiovascular risk 
in this high-risk group of patients (75).
FiGURe 2 | Atherosclerosis and chronic inflammatory disease. Patients with chronic inflammatory disease, such as rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE), exhibit an increased risk for traditional cardiovascular risk factors, plaque vulnerability, and cardiovascular events. The increase in 
cardiovascular events in this high-risk group cannot be explained entirely by the increase in cardiovascular risk factors.
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The recognition of progressive vascular disease by the use of 
circulating biomarkers is a challenge in patients with a chronic 
high state of inflammation as conventional, inflammatory bio-
markers may lack specificity in this high-risk group. Recently, 
we have been able to associate C-peptide, which is mainly 
regulated by insulin secretion and kidney function (76), to the 
presence of coronary artery calcification in patients with RA 
(77). Interestingly, the inflammatory biomarker YKL-40, which 
is thought to play a role in both atherogenesis and RA (62, 78–80), 
was a predictor for the presence of coronary artery calcification 
in patients with RA in this study, supporting the link between 
inflammation and atherosclerosis in patients with RA (Figure 2).
In addition, others found striking similarities between the 
pathogenesis of both RA and atherosclerosis, including endothe-
lial activation, inflammatory cell infiltration and activation, 
neovascularization, and collagen degradation via matrix metal-
loproteinases [for review, see Ref. (72)].
Systemic Lupus erythematosus
Patients with SLE exhibit an increased risk for mortality (81, 
82), which is in part attributed to disease activity and in part to 
increased cardiovascular deaths. This used to result in a bimodal 
mortality pattern and was described almost four decades ago 
(83). Presently, the mortality associated with disease activity 
has declined with advances in disease treatment, which results 
in increased life expectancy and a constant mortality rate over 
time (84). With these improvements in treating patients with SLE, 
cardiovascular and infectious complications are now the main 
direct cause of death among both early and late fatalities (84). 
Recently, a large retrospective cohort study in Taiwan compared 
the incidence of acute MI between patients with SLE compared 
to age- and sex-matched controls. The investigators found an 
adjusted hazard ratio of 5.11 for acute MI associated with SLE, 
which was even larger in the female population (hazard ratio 
6.28) (85). Interestingly, patients with SLE were not only associ-
ated with a higher risk of acute MI but also with an increased 
mortality post-MI (85).
Similar to what is described above for patients with RA, patients 
with SLE exhibit an increased prevalence of traditional cardiovas-
cular risk factors, including smoking, dyslipidemia, hypertension, 
and diabetes (86). However, adjustment for Framingham risk 
factors could not fully account for the increased cardiovascular 
risk in patients with SLE (87). These findings are in line with a 
recent meta-analysis including 17,187 patients, which found that 
both traditional and disease specific risk factors contribute to the 
risk in patients with SLE. Disease-specific risk factors included 
the presence of autoantibodies, neurological disorders, and to a 
lesser extent organ damage and SLE activity (88). Furthermore, 
antiphospholipid antibodies were related to mitral valve nodules 
and significant mitral regurgitation (89), suggesting that certain 
SLE-specific risk factors may also be associated with cardiovas-
cular disease but not related to atherothrombosis.
Taken together, there appears to be a link between patients 
with a chronic high state of inflammation and progressive car-
diovascular disease. Whereas RA and SLE demonstrate distinct 
immunological profiles and unique cytokine patterns [for review, 
see Ref. (90, 91, 75)], both share an increased cardiovascular 
mortality. Further studies are needed to evaluate the molecular 
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mechanisms involved in the increased cardiovascular risk in 
patients with chronic inflammation and the interplay between 
chronic inflammation, cardiovascular risk factors, and progres-
sive cardiovascular disease.
iNFLAMMATiON iN PATieNTS wiTH 
DiABeTeS MeLLiTUS
The cardiovascular vulnerability of diabetic and prediabetic 
patients is predictable by a variety of inflammatory markers. 
These are indicative of an activated innate immune system featur-
ing elevated circulating levels of IL-1, TNF-α, IL-6, and hsCRP 
(92). Among these, hsCRP has gained the most attention as a 
predictor of diabetes, cardiovascular disease, and mortality (14, 
93). In addition, low-grade inflammation is linked to activation 
of the coagulation system featuring increased levels of fibrinogen 
and PAI-1 as predisposing factor for thrombus formation (94).
A variety of mechanisms have been proposed for the initiation 
of subclinical inflammation in metabolic disease. Among these, 
obesity leads to hypertrophic adipocytes, which are unable to 
cope with an overwhelming supply of fatty acids (95). The con-
sequential release of free fatty acids into the circulation causes 
steatosis of various organs including liver and muscle (95). 
Limited lipid storage capacity of their organelles results in meta-
bolic disturbance and oxidative stress, which has been termed 
lipid toxicity. The consequential cellular damage and apoptosis 
requires debris-clearing recruitment of macrophages. These 
eliminate cell fragments as a prerequisite for tissue regeneration. 
Low-grade inflammation accompanying this cellular turnover is 
beneficial and part of a healing process. Persistence of pathogenic 
stimuli with ongoing cellular damage, however, leads to chronic 
inflammation and disturbed tissue integrity (96). Initiation of 
fibrosis may lead to an irreversible scaring process as found for 
steatohepatitis with transition to liver cirrhosis.
Saturated fatty acids further serve as ligands for pattern rec-
ognition receptors including TLR2 and 4 (97, 98). These provide 
a primitive line of defense of the innate immune system able to 
recognize a variety of microbial fragments and cell debris. TLRs 
signal downstream to various inflammatory pathways, includ-
ing NF-κB and MAP-kinase, with secretion of inflammatory 
cytokines, including TNF-α, IL-1, and IL-6. In addition, activation 
of NF-κB causes direct inhibition of the insulin receptor cascade 
as an alternative mechanism of inflammation-mediated insulin 
resistance (99). Genetic or pharmaceutical inhibition of NF-κB 
improves glucose metabolism in mice and men. Indeed treatment 
with salsalate – a prodrug of salicylic acid, which inhibits NF-κB 
at high doses  –  lowers fasting glucose in non-diabetic, obese 
individuals (99, 100). Salsalate, however, also slightly increases 
plasma LDL-cholesterol levels and was ineffective in improving 
flow-mediated dilatation in patients with diabetes, questioning 
its clinical utility (100). Another anti-inflammatory strategy in 
metabolic disease, which has advanced to the clinics, is blockade of 
the IL-1 receptor system. This improved glucose metabolism and 
insulin sensitivity in small clinical studies and was associated with 
a reduction of inflammatory serum parameters (101). Blockade 
of the IL-1 system is currently evaluated in a large cardiovascular 
endpoint study (CANTOS) in which the IL-1-directed antibody 
canakinumab is tested versus placebo in a randomized trial in 
17,200 stable, post-MI patients with persistent high CRP levels 
(102). A dedicated sub-study further investigates the effect of IL-1 
system blockade on glucose metabolism and insulin resistance 
with trial termination being expected in 2017. The efficacy of 
inflammation targeting therapies in metabolic disease is further 
investigated in the Cardiovascular Inflammation Reduction Trial 
(CIRT) using low-dose methotrexate (target dose 15–20 mg/week) 
treatment. This study randomizes 7000 prior MI patients with 
either type 2 diabetes or the metabolic syndrome with an average 
follow-up period of 3–5 years expecting termination in 2018 (103).
More recently, metabolic inflammation has further been 
attributed to a disturbed intestinal barrier function (104). 
Increased circulating concentrations of endotoxin are detected 
in patients with obesity and diabetes with direct associations 
to cardiovascular disease (105). A disturbed intestinal barrier 
enables the passive diffusion of bacterial fragments and lipopoly-
saccarides across the intestinal mucosa. Interestingly, this seems 
to be modulated by dietary factors with high nutritional fat intake 
promoting endotoxin absorption (106). Circulating endotoxin 
serves as a ligand for TLR2 and 4 with activation of the innate 
immune system. Chronic low-dose endotoxin application was 
consequently found to cause obesity and insulin resistance in 
rodent models while knockout of TLR4 prevented diet-induced 
obesity, glucose intolerance, and atherosclerosis (107–109). 
Furthermore, mice lacking the functional LPS receptor CD14 
were resistant to diet-induced obesity and related disorders (110) 
while antibiotic eradication of the gut flora led to reduced meta-
bolic inflammation, insulin resistance, and fat mass development 
(111). In consequence, germ-free mice were protected from high-
fat diet-induced inflammation (112). Modulation of the intestinal 
microbiome as a source for endotoxin generation might therefore 
provide a new treatment strategy for diabetes and cardiovascular 
disease prevention.
These observations demonstrate a close interaction between 
the immune system and metabolism which is particularly present 
in patients with diabetes. Activation of the immune system does 
thereby not depend on an external stressor but is the conse-
quence of overnutrition as an endogenous stressor. Concepts of 
anti-inflammatory therapies might prove effective in improving 
diabetes and cardiovascular outcome.
CONCLUSiON
Over the last 30 years, inflammation has increasingly been recog-
nized as an important pathophysiological link between vascular 
disease, atherothrombosis, metabolic disorders, and chronic 
autoimmune diseases. A plethora of mediators, such as cytokines, 
chemokines, and adipokines, released from various cells in dif-
ferent organs contribute to both local and remote stimulations 
of inflammatory cells, thus creating a network of interactions 
at different levels in the organism. Future therapeutic strategies 
need to be developed to examine how and by which tools this 
interaction can be targeted to modulate cardiovascular disease in 
high-risk patients.
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